Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
11C-CFT
- Development stage
- Unknown
- Lead developer
- Luye Pharma
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
11C-CFT is a radiopharmaceutical used as a positron emission tomography (PET) tracer to visualize and quantify the dopamine transporter (DAT) in the brain. It is a cocaine analog that binds with high affinity and selectivity to presynaptic DAT, primarily located in the striatum (caudate and putamen). By measuring DAT density, 11C-CFT PET imaging serves as a biomarker for the integrity of nigrostriatal dopaminergic neurons. It is extensively used in clinical research and diagnosis to differentiate Parkinson's disease from other movement disorders, assess disease progression, and evaluate the occupancy of dopamine transporters by therapeutic drugs like toludesvenlafaxine. The tracer is typically produced in-house by facilities equipped with a cyclotron due to the short half-life of the Carbon-11 isotope.
- Other names
- 11C-2β-carbomethoxy-3β-(4-fluorophenyl) tropane11C-methyl-N-2β-carbomethoxy-3β-(4-fluorophenyl)-tropane[11C]CFT11C-WIN 354282β-carbomethoxy-3β-(4-fluorophenyl) tropane
02
Targets
DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on 11C-CFT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 11C-CFT.